Comparison · NCT02691013-257d10cf
Ramelteon vs Placebo: Number of Participants With Delirium
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Ramelteon vs Placebo: Number of Participants With Delirium. Trial comparisons, record NCT02691013-257d10cf. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02691013-257d10cf
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.322 | 0.217 | 0.449 | wilson | |
| Risk in group 2 | 0.379 | 0.266 | 0.508 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0573 | -0.223 | 0.113 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.849 | 0.517 | 1.39 | log | |
| Odds ratio, group 1 over group 2 | 0.777 | 0.363 | 1.66 | log | |
| Number needed to treat, for one fewer participant with the outcome on Ramelteon than on Placebo | 17.5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Ramelteon | Patients will receive Ramelteon 8mg every evening starting the night prior to the procedure for a maximum of 7 nights total.~Ramelteon | 19 | 59 | OG001 |
| Group 2 | Placebo | Patients will receive a Placebo tablet every evening starting the night prior to the procedure for a maximum of 7 nights total.~Placebo | 22 | 58 | OG000 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Delirium
- Description
- Measured twice daily over the course of the ICU stay using the Confusion Assessment Method instrument
- Time frame
- Twice daily for up to 10 days
- Population
Source ClinicalTrials.gov
Trial
- Title
- The Impact of Ramelteon on Sleep and Delirium in Patients Who Undergo Pulmonary Thromboendarterectomy (PTE) Surgery
- NCT number
- NCT02691013
- Phases
- NA
- Conditions
- Delirium, Sleep Deprivation
- Interventions
- Ramelteon, Placebo
- Lead sponsor
- University of California, San Diego
- Results first posted
- 2019-09-20
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02691013?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02691013-257d10cf